arGEN-X gins $13.6M in new funds for mAB work

The Dutch antibody developer arGEN-X has garnered $13.6 million in a Series A, which will be used to develop its antibody platform and create a slate of mAb candidates for development. The deal was co-led by Forbion Capital Partners and LSP while  KBC Private Equity, BioGeneration Ventures and existing shareholders Erasmus MC Biomedical Fund and Thuja Capital Healthcare Funds joined the syndicate.

 "We are impressed by arGEN-X's SIMPLE Antibody platform, its strong proprietary position and its ability to efficiently generate gold standard, human antibodies as demonstrated by the company's lead program," says LSP partner John de Koning, PhD. "We believe arGEN-X is well positioned to play an important role in tomorrow's human monoclonal antibody market." The company's release touts the round as one of the largest of its kind for the past 12 months.

- read the arGEN-X release for more information 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.